Last reviewed · How we verify
Herpes Zoster Vaccine, Live
This live attenuated vaccine stimulates the immune system to recognize and respond to varicella-zoster virus, preventing herpes zoster (shingles) reactivation.
This live attenuated vaccine stimulates the immune system to recognize and respond to varicella-zoster virus, preventing herpes zoster (shingles) reactivation. Used for Prevention of herpes zoster (shingles) in adults with prior varicella infection.
At a glance
| Generic name | Herpes Zoster Vaccine, Live |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened form of varicella-zoster virus that replicates in the body without causing disease, triggering both cellular and humoral immune responses. This boosts immunity against the virus, reducing the risk of herpes zoster reactivation in individuals with prior chickenpox infection and decreasing the severity of disease if breakthrough infection occurs.
Approved indications
- Prevention of herpes zoster (shingles) in adults with prior varicella infection
Common side effects
- Injection site erythema
- Injection site pain or swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herpes Zoster Vaccine, Live CI brief — competitive landscape report
- Herpes Zoster Vaccine, Live updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI